Get the Stockscreener App
9.41
5.33%
-0.53
Mink Therapeutics Inc stock is traded at $9.41, with a volume of 13,611.
It is down -5.33% in the last 24 hours and down -18.81% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
See More
Previous Close:
$9.94
Open:
$9.87
24h Volume:
13,611
Relative Volume:
0.86
Market Cap:
$48.02M
Revenue:
Net Income/Loss:
$-12.49M
P/E Ratio:
-3.1739
EPS:
-2.9648
Net Cash Flow:
$-5.93M
1W Performance:
-12.22%
1M Performance:
-18.81%
6M Performance:
-33.40%
1Y Performance:
-34.83%
1-Day Range:
$9.38
$10.10
1-Week Range:
$9.38
$11.24
52-Week Range:
$8.4801
$16.93
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
9.41 | 48.02M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
Mink Therapeutics CEO Buell sells $73,265 in stock for tax obligations - Investing.com Nigeria
Form 4 Mink Therapeutics Inc: Jennifer Buell (Director, CEO) For: 11 October - Investing.com Nigeria
MiNK Therapeutics (INKT) CEO sells 6,938 shares solely to cover taxes owed upon vesting. - Stock Titan
Form 144 MiNK Therapeutics For: 13 October By Investing.com - Investing.com Nigeria
CEO lists 6,938 shares for sale at MiNK Therapeutics (Nasdaq: INKT) following stock award vesting. - Stock Titan
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance Singapore
Orbit International Closes on New $6,000,000 Credit Facility; Also Completes $4,075,000 Private Placement - The Manila Times
A cell therapy enabled killing of immunotherapy-resistant colon cancer cells in a lab model - Stock Titan
MiNK Therapeutics’ agenT-797 Selected for ARPA-H BoSS Program to Advance Room-Temperature Cell Therapy Storage - Quiver Quantitative
Mink Therapeutics, Inc. Announces Selection of Clinical-Stage Agent-797 Inkt Platform for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy - marketscreener.com
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
MiNK Therapeutics (INKT) insider reports stock trades - Stock Titan
Insider at MiNK Therapeutics (NASDAQ: INKT) reports stock transactions - Stock Titan
Insider at MiNK Therapeutics (INKT) reports new stock trades - Stock Titan
Mink Therapeutics, Inc. (INKT) Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MiNK Therapeutics (INKT) Drops 6.1% to $11.06 on Biotech Sector WeaknessWyckoff Distribution - vinanet.vn
MiNK (INKT) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Reported Period; After Earnings: Shares Move Lower 3.11% in Latest TradingTech Earnings Analysis - vinanet.vn
MiNK Therapeutics Earnings Call Highlights ARDS Push - TipRanks
MiNK (INKT) Move: Finishes 4.99% Higher at $12.20 in the Current Update; Next Test: the $11.59 to $12.81 Range Remains in Focus in the Latest SessionCalendar Spread Trade - siam.in
MiNK (INKT) Move: Moves 0.15% Up to $11.37 for the Current Session; Price Setup: Support at $10.80 and Resistance at $11.94 Frame the Range at the CloseAI Trade Signals - vinanet.vn
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.ca
Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst - MarketBeat
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.com
MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiNK Therapeutics (INKT) Slides 5.17% as Biotech Stock Tests Key Support at $10.45AAII Neutral - vinanet.vn
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha
MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
META_TITLE_QUOTE - Yahoo Finance
MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat
MiNK Therapeutics Q2 Earnings Call Highlights - TradingView
MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade
INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView
MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛
Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com
Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com South Africa
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Nigeria
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com India
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com UK
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com India
MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mink Therapeutics Inc Stock (INKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Buell Jennifer | Officer |
Oct 12 '26 |
Proposed Sale |
10.56 |
6,938 |
73,275 |
0 |
| Ryan Barbara | Director |
Jun 04 '26 |
Sale |
12.76 |
1,500 |
19,141 |
21,969 |
| Ryan Barbara | Director |
Mar 10 '26 |
Sale |
15.40 |
1,300 |
20,017 |
20,406 |
| Ryan Barbara | Director |
Mar 09 '26 |
Sale |
10.17 |
200 |
2,034 |
21,706 |
| Ryan Barbara | Director |
Mar 02 '26 |
Sale |
10.83 |
100 |
1,083 |
21,906 |
| Ryan Barbara | Director |
Feb 27 '26 |
Sale |
10.86 |
400 |
4,343 |
22,006 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):